Sontra Medical Corp., which just last month was ready to close the doors to its Franklin home and lay off its employees, announced the appointment of Walter Witoshkin to its board of directors.
Witoshkin is chairman and CEO of QuantRx, which he joined in 2005. Witoshkin has had a 40-year career in the healthcare and biomedical industries, including a stint as vice president of business development and CFO of SmithKline Beecham, now Glaxo SmithKline.
Sontra bills itself as “a technology leader in transdermal science,” and is developing a non-invasive glucose monitor for diabetes patients and the intensive care market.
In late December, Sontra said it would close its doors amid Nasdaq’s third threat to delist the company’s stock. The company was saved in early January when Sherbrooke Partners LLC along with some of the company’s board members and management team spent about $600,000 on about 6 million shares of company stock. Witoshkin contributed $5,000 toward that effort, according to a company filing with the Securities and Exchange Commission.
Sontra’s board was down at least one person after Gary Kohler announced his resignation from the board on Feb. 5.
